Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Merck & Company ( (MRK) ) has released its Q3 earnings. Here is a breakdown of the information Merck & Company presented to its ...

The investment community will be closely monitoring the performance of Merck in its forthcoming earnings report. The company is scheduled to release its earnings on October 31, 2024. On that day ...

Belen Garijo took charge of German drug-to-semiconductor group Merck KGaA with the tailwind ... her strategy to reposition the Darmstadt-based company as a global player in oncology and immunology.

Even when we zoom out, Merck hasn't performed particularly well in recent years. The company has significantly trailed the S&P 500 over the past decade. Does that mean investors should stay away ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

now accounting for more than a third of its total sales there has been pressure on the company to diversify. Dean Li, president of Merck Research Laboratories, told the meeting that cardiovascular ...

Merck’s stock fell Thursday morning, despite the company beating profit and sales estimates for the third quarter.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Joerg Koglin, senior vice president and head of ...

In the latest market close, Merck (MRK) reached $106.64, with a +0.28% movement compared to the previous day. The stock's change was more than the S&P 500's daily loss of 0.05%. Meanwhile, the Dow ...